cyrilzakka/clinical-trials huggingface dataset:
A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years

This is an observational, non comparative, non-randomised, open-label, retrospective, single centre study planned to collect the data of subjects diagnosed with multiple sclerosis (MS) as per Poser or McDonald criteria between 1997 and 2007 in Taiwan. The clinical features and annual relapse rate in the first five years after the onset of disease have been compared between conventional and optico-spinal MS in the earlier studies. This study aims to understand the clinical care pathway of MS subjects and facilitate the subject's diagnosis before converting to MS.

Multiple Sclerosis is a chronic, inflammatory disease of the central nervous system (CNS) and is characterised by areas of demyelination, or plaques in the CNS. The disease is twice as prevalent in women as compared to men and causes considerable disability over time and continues for the lifetime of the subject. Subjects with MS are thought to have a genetic predisposition for the disease, though environmental factors such as geographic location and possibly viral infection also play an important role in the process of development of the disease.

OBJECTIVES

Primary objective:

* To understand the clinical care pathways of MS subjects at the site over the last 10 years in order to raise the medical attention of MS diagnosis

Secondary objective:

* To review the pattern of MS treatment regimens in MS subjects at a particular site between 1997 and 2007

Eligibility Criteria:
Inclusion Criteria:

* Subjects diagnosed with MS as per Poser or McDonald criteria between 1997 and 2007
* EDSS before treatment was available if subject has started the disease modifying drug treatment.
A Prognostic Model to PREDICT Relapse of Depression in Primary Care

The investigators aim to develop a prognostic model to predict the risk of relapse within 6-8 months of patients entering remission. The long-term objective is to facilitate more efficient targeting of evidence-based relapse prevention strategies to these patients.

Most patients with depression are treated in primary care by general practitioners (GPs). Relapse of depression is common and leads to considerable morbidity and decreased quality of life for patients. Estimates suggest that at least 50% of patients treated for depression will relapse after a single episode. The majority of these will relapse within 6 months and the risk of relapse increases for each successive episode of depression. GPs see a largely undifferentiated case-mix of patients and, once patients with depression reach remission, there is limited guidance and no validated tools to help GPs stratify patients according to risk of relapse.This study will potentially derive a statistical model to predict relapse of depression in remitted depressed patients in primary care.

The investigators have created a longitudinal cohort of patients drawn from seven randomised controlled trials (RCTs) of non-pharmacological primary care-based interventions for depression and one longitudinal cohort study. The investigators will use logistic regression to predict the outcome of relapse of depression within 6-8 months. The investigators plan to include the following well-evidenced relapse predictors in the model: residual depressive symptoms; number of previous episodes of depression; co-morbid anxiety; and severity of the index episode. They will also control for RCT intervention received by participants.

If sample size and availability of predictor information allows, the investigators will include the following predictors in an exploratory analysis: age; relationship status; multi-morbidity; employment status; gender; and ethnicity. Generalisability will be assessed through internal-external cross-validation and net benefit will be explored.

Eligibility Criteria:
Inclusion Criteria:

* Remitted depressive disorder

Exclusion Criteria:

* Co-existing severe mental illness
Acute Coronary Disease (ACS)- Strain

Examination of probable distinction between cardiac or non- cardiac thoracal disorder via echocardiographic myocardial strain analysis

Patients with cardiac disorder have to undergo time- consuming and expensive examinations such as laboratory of cardiac biomarkers or ischemic diagnostic. To save time and money in this observational registry the probable distinction between cardiac and non- cardiac disorder in patients with vague thoracal disorder and the probability for coronary artery disease (determined via Grace Score) is examined via echographic myocardial strain analysis in 300 patients retrospectively to establish a cut off value corresponding to acute coronary disease also to prevent coronary angiography. Therefore patients undergo echography routinely with consecutive evaluation of systolic, diastolic and strain analysis to elevate exact statements with reference to deformation of the myocard and its velocity. Several study have shown that these strain parameters (circumferential and radial strain) enable vitality and ischemic diagnosis and therefore could be eligible for this purpose.

Eligibility Criteria:
Inclusion Criteria:

* thoracal cardiac or non cardiac disorder
* signed informed consent

Exclusion Criteria:

* glomerular filtration rate (GFR) \< 60 ml/min
* angina pectoris
* acute myocardial infarction within 3 months prior inclusion
* pregnancy
Contrast Training, Post-activation Countermovement Jump Performance in High Strength Male

The study investigated the effects of three contrast training sessions in a week on post-activation countermovement jump performance in high strength male.

Previous researches indicated that the primary contributor of contrast training to improving explosive performance might be the phenomenon of post-activation performance enhancement (PAPE), with emphasis on conducting plyometric training at the optimal PAPE time. However, the PAPE appeared to be susceptible to fatigue and delayed potentiation of neuromuscular performance. Thus, its applicability in practical training is not yet clarified. The purposes of this study are to: 1) examine the effects of three contrast training sessions in a week on individual and group's PAPE and the optimal timepoint of PAPE; 2) assess the intrasession and intersession reliability of the optimal PAPE timepoints of both individuals and groups; 3) determine the relationship between kinematic parameters during resistance training and PAPE.

Qualified participants will visit the laboratory five times for experimental familiarization, One repetition maximum (1RM) of parallel squat test, and three contrast training sessions, with each contrast training session consisting of three sets of parallel squats in a week. Alongside this, countermovement jump tests will be conducted before the first set of squats and at 1, 3, 5, 7, 9, and 11 minutes after each squat set, with the kinematic parameters of the parallel squats also being collected.

Eligibility Criteria:
Inclusion Criteria:

* Least 2 years of resistance training experience.
* Least 1.75 times body weight of squat 1RM
* Currently engaged in regular exercise training.

Exclusion Criteria:

* Skeletal muscle injury within the past six months.
* Non-responders to PAPE
Perioperative Patient Skin Antiseptic Preparation Evaluation

This study will evaluate a new topical skin antiseptic perioperative preparation and the standard of care to determine efficacy on the rates of surgical site infections of surgical patients. Safety will also be assessed.


Eligibility Criteria:
Inclusion Criteria:

1. Be male or female and at least 18 years of age.
2. Be able to verbalize an understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English.
3. Be planning to undergo clean (class I wound) or clean-contaminated (class II wounds) surgery.
4. Expect to be available for up to 30-days after the surgery.

Exclusion Criteria:

1. Active infection or fever including evidence of infection at or adjacent to the operative site.
2. Immunosuppressed.
3. Kidney/liver failure.
4. Immunosuppressive therapy (chemotherapy, steroids) within the previous 1 week.
5. Any history of allergy to chlorhexidine or isopropyl alcohol or any other component in ZuraGard including citric acid, sodium citrate, methylparaben, or propylparaben, and FD\&C Yellow #6.
Running Title: PPAR-γ, RXR-α, and VDR Expressions in Periodontitis

Objective: The present study aimed to determine the expressions of nuclear receptors PPAR (Peroxisome proliferative activator receptor)-γ, RXR (Retinoid X receptor)-α, and vitamin D receptor (VDR) in healthy volunteers and periodontitis patients with different grade involvement.

Methods: Group-1; healthy individuals, Group-2; periodontitis patients-stage 3 grade B, (H-GradeB), Group-3; periodontitis patients-stage 3 grade C, (D-GradeC). Clinical parameters as plaque index (PI), gingival index (GI) and clinical attachment levels (CAL) were measured. Fibroblast and inflammatory cells, PPAR-γ, RXR-α, and VDR levels were determined in histological slides.


Eligibility Criteria:
Inclusion Criteria:

* systemic health
* no drug use
* no previous periodontal treatment within six months
* no tobacco use

Exclusion Criteria:

* pregnant or lactating women
* patients used antibiotics in the last 6 months
Testing a 32-channel Transmit/Receive MRI Head Array

Magnetic resonance imaging (MRI) is a diagnostic tool in medicine that generates high quality images of the human body without the use of x-rays. Volunteers will be asked to participate in a study to evaluate improved MRI hardware that can be used to enhance the ability of MRI as a diagnostic tool. Specifically, this hardware is designed to acquire high quality images of the brain. This MRI hardware will eventually be integrated into a positron emission tomography (PET) system, which will be able to detect trace amounts of brain disease and/or brain function simultaneously with MRI. The combined system is known as a PET/MRI. For the purposes of this test, the investigators are just evaluating the MRI hardware, which will be installed in a plastic mockup of the PET system.


Eligibility Criteria:
Inclusion Criteria:

* 18-75 years old
* Must be able to give consent
* Must complete the MRI screening questionnaire

Exclusion Criteria:

* Contraindications to MRI procedure
Nicotinamide in the Treatment of Psoriasis

This study will determine if combination of topical calcipotriol and nicotinamide is more effective than calcipotriol alone in treatment of psoriasis.

Current treatment strategies of psoriasis are not completely satisfactorily. By inhibiting inflammatory cytokines, nicotinamide may enhance the effects of current topical treatments. Preliminary studies have shown that nicotinamide, which is a vitamin B derivative, is effective in the treatment of psoriasis. According to lack of data, we will investigate the beneficial effects of adding nicotinamide to calcipotriol for patients with mild to moderate psoriasis.

Eligibility Criteria:
Inclusion Criteria:

* Men and women of 18 to 65 years old,
* Mild to moderate psoriasis; patients must have had less than 15% of the involved body surface, symmetrical plaques (bilateral lesions) or two plaques at least 5 cm apart on the same side of the body with plaque size greater than 2 × 2 cm, but smaller than 15 × 15 cm.
* Willingness to participate

Exclusion Criteria:

* Those who used any medication or niacin and multi-vitamins two weeks, or anti-psoriatic systemic drugs or beta-blockers one month prior to the study,
* Pregnant women,
* Those with the history of renal, hematologic, liver and major psychiatric diseases,
* Those with only scalp, nail, flexural, palmoplantar, or pustular psoriasis.
Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS

The purpose of this study is to find out if cannabis-based medicine compared to a dummy medicine (placebo that contains no active ingredient) can help the central neuropathic pain patients experience as a result of multiple sclerosis. This type of pain "central neuropathic pain" is described as shooting, stabbing, burning or searing like sensation, which is often worse at night.

GW has shown in phase II and III studies that Sativex has analgesic properties that are effective in relieving neuropathic pain. These studies suggested that Sativex is well tolerated and may also improve sleep and quality of life. GW is conducting this study to further demonstrate these effects.

Eligibility Criteria:
Inclusion Criteria:

* Any disease sub-type of MS of at least two years duration
* Central neuropathic pain (CNP) of at least three months and expected to remain stable for the study duration
* Moderate CNP defined by NRS pain score at baseline sum to at least 24
* Subject established on or previously tried and failed analgesic therapy for CNP
* If receiving disease modifying medications, stable dose for 3 months and maintained for study duration

Exclusion Criteria:

* Subjects whose identified pain is likely to be nociceptive, musculoskeletal (including spasms) peripheral neuropathic or psychogenic in origin, or due to trigeminal neuralgia.
* Other non central neuropathic pain of a severity which is likely to interfere with the patients assessment of CNP
* medical history suggests subject is likely to relapse/remit during course of study
* history of schizophrenia (including family history), other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with MS
* known or suspected history of alcohol abuse, epilepsy or recurrent seizures or hypersensitivity to cannabinoids
* travel outside of the country of residence planned during the study
* significant cardiac, renal or hepatic impairment
* subjects with current recreational cannabis, medicinal cannabis or synthetic cannabinoid based medications within 3 months prior to study entry and unwilling to abstain for the duration of the study
Toradol v. Celecoxib for Postoperative Pain

Randomized control trial between ketorolac versus celecoxib for postoperative pain following hysterectomy.

Purpose:

To determine if Celebrex (Celecoxib) is as effective as Toradol (Ketorolac) at controlling postoperative pain when given in addition to standard postoperative pain control regimens.

Rationale:

Toradol (Ketorolac) is currently used by many surgeons as adjuvant therapy in addition to standard narcotics in managing immediate postoperative pain. Toradol (Ketorolac) is a non-steroidal anti-inflammatory drug that acts as a non-selective cyclooxygenase (COX), inhibiting COX-1 and COX-2 isoforms. (Toradol) Ketorolac has been associated with significant complications including postoperative bleeding and acute renal insufficiency. Celebrex (Celecoxib) is a selective COX-2 inhibitor that has been associated with adverse cardiovascular outcomes in patients with pre-existing cardiac disease but not with postoperative bleeding or renal insufficiency. Celebrex (Celecoxib) has also been shown to control postoperative pain but has never been compared to Toradol (Ketorolac).

Population:

Patients undergoing hysterectomy on the gynecology oncology service.

Design:

Randomized control trial.

Procedures:

All patients will receive a standard postoperative pain regimen with oral Tylenol (Acetaminophen), oral Lortab (Hydrocodone/Acetaminophen) as needed, and IV Dilaudid (Hydromorphone) as needed.

Randomization: Each participant will be assigned a number using a random number generator for assignment to one of the two postoperative pain regimens:

Arm 1:

Patients ages 18-65 will receive IV Toradol (Ketorolac) 30mg q6 hrs after their operation for 48 hrs or until hospital discharge if patients are discharged home in less than 48 hours after their operation.

\*\*Patients over age 65 will receive IV Toradol (Ketorolac) 15mg q6hrs instead of 30mg

Arm 2:

Patients who will receive oral Celebrex (Celecoxib) 400mg 1 hour prior to their procedure then 200mg oral twice daily for a total of seven days. Patients discharged prior to 7 days will be given a prescription for Celebrex (Celecoxib) to complete a total of 7 days.

Following surgery all patients will be given a postoperative questionnaire at the day of surgery, which was returned at the two week postoperative visit, examining time until return to ADLs, days of narcotic use, and number of narcotic pills used.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing hysterectomy

Exclusion Criteria:

* Coronary Artery Disease
* Peptic Ulcer Disease
* Chronic Renal Disease
* Liver disease
* Alcohol Abuse
* Daily narcotic usage
* Narcotic use 24 hours prior to surgery
* Crohn's Disease
* History of myocardial infarction
* History of stroke
* Preoperative hematocrit less than 24
* Asthma
* Ulcerative Colitis
* Diverticulitis
* Aspirin Allergy
* Sulfonamide Allergy
* Pre-operative pain score of greater than 3
* Patients undergoing procedures that may involve bowel resection or bowel reanastomosis.
* Allergy to any non-steroidal anti-inflammatory drug
* Cardiac anomaly or disease
* Congestive Heart Failure
Effects of Mini Implant Facilitated Micro-osteoperforations on the Alignment of Mandibular Anterior Crowding

The primary aim of the present study is to evaluate the the efficacy of micro-osteoperforation (MOPs) perfomed by mini-implant (MI) screw In improving alignment of mandibular anterior teeth

Primarily the present study is designed to evaluate the efficacy of micro-osteoperation (MOPs) perfomed by mini-implant (MI) screw In improving alignment of mandibular anterior teeth. Additionally, the possibility of inducing root resorption, and patient perception of pain during the initial phase of treatment.

Subjects and Methods: Orthodontic patients aged 17-25 years old, non-extraction treatment with lower anterior crowding of 4-6 mm using Little's irregularity index. Outcome measures included the amount of crowding using Little's irregularity index (LII), apical root resorption, and pain perception. The effectiveness of alignment will be tested using t-test, while root resorption and pain perception will be tested by the Mann-Whitney U test, and Wilcoxon signed-rank test (P\<0.05).

Eligibility Criteria:
Inclusion Criteria:

1. Age range between 17-25years
2. Non-extraction treatment in the mandibular arch
3. Presence of full complement of dentition from first molar to first molar
4. Mandibular anterior irregularity index between 4-6 mm
5. Patient with healthy periodontium and no attachment loss of \>2 mm

Exclusion Criteria:

1. Previous orthodontic treatment
2. Presence of primary or missing permanent teeth in the mandibular anterior area
3. Medical problems that affect tooth movement.
Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE)

This study will evaluate the next generation WATCHMAN Left Atrial Appendage (LAA) Closure Device as implanted in patients with non-valvular atrial fibrillation (AF) with a CHADS2 stroke risk stratification score of 1 or greater. This is a prospective, non-randomized study to evaluate the initial use of the next generation WATCHMAN Device.


Eligibility Criteria:
Key Inclusion Criteria:

* Paroxysmal, persistent, or permanent non-valvular atrial fibrillation
* Eligible for long-term Warfarin therapy;
* Eligible to come off Warfarin therapy if the LAA is sealed
* Calculated CHADS2 score of 1 or greater

Key Exclusion Criteria:

* New York Heart Association Class IV Congestive Heart Failure
* Recent MI (within 3 months)
* ASD and/or atrial septal repair or closure device
* Resting heart rate \>110 bpm
* Has an implanted mechanical valve prosthesis
* Left atrial appendage is obliterated
* Has undergone heart transplantation
* Has symptomatic carotid disease
* Contraindicated for aspirin
* LVEF \< 30%
* Cardiac Tumor
DarDar Nutrition Study in HIV Breastfeeding Women

This study being conducted in Dar es Salaam, Tanzania, to determine if a protein-calorie supplementation (PCS) and micronutrient supplement (MNS) will have an impact on health outcomes for HIV-infected pregnant women and their infants.

In resource poor regions of the world where HIV is endemic, especially countries in sub-Saharan Africa, nutrition plays a critical role in HIV disease. Nutrition affects the health of HIV-infected women and children, and may influence the risk of mother to infant transmission of HIV through breast milk. Nutrition influences the risk of tuberculosis (TB) and TB disease severity. Existing research has focused on the role of micronutrients in HIV disease outcomes but has not addressed the role of protein calorie supplementation (PCS) in subpopulations of patients with HIV disease at high risk, specifically, HIV-infected women who are either breast feeding or have active TB. Our hypotheses are that administration of a culturally acceptable PCS is a practical, sustainable and effective strategy to: 1) decrease HIV viral load in plasma and breast milk of breast feeding women, enhance passively transferred immune mediators in breast milk, and improve HIV outcomes in women and their breast-fed infants and, 2) decrease HIV viral load, enhance TB-specific T cell immunity, and improve outcomes in women with HIV and active TB.

Eligibility Criteria:
Inclusion Criteria:

* HIV+ women
* 2nd trimester of pregnancy
* Residency in Dar for duration of breastfeeding
* Plan to exclusively breastfeed

Exclusion Criteria:

* High risk pregnancy (e.g., diabetes, pre-eclampsia)
* Women with allergy to components of PCS
Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis

Patients who have agreed to participate in the study will complete the MRI protocol as part of routine care, to which four additional 20-minute sequences will be added.

MRI of routine care in the context of MS includes at least the following sequences:

* 3D T1 TFE (2 minutes)
* T2 TSE (2 minutes)
* 3D FLAIR (3 minutes)
* SWI EPI 0.6 iso (7 minutes)

The sequences added by the search are:

* SWI non EPI QSM 6 echo (10 minutes)
* SWI EPI in resolution equivalent to non-EPI SWI (3 minutes)
* SWI EPI to TR equivalent to SWI non EPI (6 minutes)

These sequences will be acquired before or after the injection of gadolinium (if present in the examination of routine care). For examinations carried out with injection, the order of carrying out the 4 post-injection SWI sequences will be random.


Eligibility Criteria:
Inclusion Criteria:

* Patients over 18
* With MS defined according to the McDonald's revised clinical or radiological spatial and temporal dissemination criteria, with onset of symptoms \<5 years
* To benefit as part of care from an MRI with or without injection of gadolinium
* Express consent to participate in the study
* Affiliate or beneficiary of a social security scheme

Exclusion Criteria:

* Patient benefiting from a legal protection measure
* Pregnant or breastfeeding woman